Knight Therapeutics Launches Wynzora for Psoriasis Vulgaris in Canada Following Health Canada Approval – Knight Therapeutics

Knight Therapeutics Inc. announced the launch of Wynzora, a uniform white aqueous cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), in Canada.
Wynzora is indicated for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12 and older.

“The launch of Wynzora in Canada reflects our commitment to continuing to grow our Canadian platform and bring innovative treatment options to patients. Wynzora’s unique aqueous cream formulation, enabled by PAD Technology, offers patients and healthcare providers a clinically proven option that combines efficacy with ease of use, an important consideration for a chronic condition that requires long-term management.” – Samira Sakhia, President and Chief Executive Officer, Knight Therapeutics Inc.

Knight obtained the Canadian rights to Wynzora through its June 2025 acquisition of the assets of Paladin Pharma Inc. (“Paladin”). Paladin had entered into a license agreement with MC2 Therapeutics Ltd. (“MC2”) to commercialize Wynzora in Canada in November 2024. MC2 is a private pharmaceutical company headquartered in Hørsholm, Denmark and in Guildford, United Kingdom. Knight announced Health Canada approval of Wynzora in December 2025.